Literature DB >> 19910750

The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease.

Carlos Gonzalez-Juanatey1, Tomas R Vazquez-Rodriguez, Jose A Miranda-Filloy, Trinidad Dierssen, Ines Vaqueiro, Ricardo Blanco, Javier Martin, Javier Llorca, Miguel A Gonzalez-Gay.   

Abstract

We conducted the present study to determine whether subclinical macrovascular atherosclerotic disease was present in patients with ankylosing spondylitis (AS) without clinical history of cardiovascular disease. We also sought to establish whether demographic or clinical features of the disease may influence the development of subclinical atherosclerotic disease in a series of patients with AS seen at a community hospital. We recruited 64 patients who fulfilled the modified New York diagnostic criteria for AS from Hospital Xeral-Calde, Lugo, Spain. We excluded patients seen during the recruitment period who had cardiovascular disease or renal insufficiency. We also studied 64 matched controls. Carotid artery intima-media thickness (IMT) and carotid plaques were measured in the right common carotid artery. The study was performed using high-resolution B-mode ultrasound.Patients with AS exhibited greater carotid IMT than did matched controls (mean +/- SD, 0.74 +/- 0.21 mm vs. 0.67 +/- 0.14 mm; p = 0.01; differences of means, 0.077; 95% confidence interval, 0.016-0.139). Carotid plaques were more commonly observed in patients with AS than in controls (19 [29.7%] vs. 6 [9.4%], respectively; p = 0.03). The best predictors for carotid plaques in patients with AS were erythrocyte sedimentation rate (ESR) at time of disease diagnosis (odds ratio [OR], 1.18; 95% confidence intervals [CI], 1.04-1.33; p = 0.01) and duration of disease (OR, 1.39; 95% CI, 1.01-1.92; p = 0.05). In contrast, there was no significant correlation between carotid IMT and either ESR or C-reactive protein in this study. Results of the present study show that patients with AS without clinically evident cardiovascular disease have a high prevalence of subclinical macrovascular disease in the form of increased carotid IMT and carotid plaques compared to matched controls.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19910750     DOI: 10.1097/MD.0b013e3181c10773

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  42 in total

1.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 3 Clinical symptoms].

Authors:  U Kiltz; M Rudwaleit; J Sieper; D Krause; J-F Chenot; A Stallmach; S Jaresch; U Oberschelp; E Schneider; B Swoboda; H Böhm; A Heiligenhaus; U Pleyer; W-H Böhncke; M Stemmer; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

2.  Association between arterial stiffness, disease activity and functional impairment in ankylosing spondylitis patients: a cross-sectional study.

Authors:  Claudiu Avram; Răzvan Gabriel Drăgoi; Horațiu Popoviciu; Mihai Drăgoi; Adina Avram; Elena Amaricăi
Journal:  Clin Rheumatol       Date:  2016-05-12       Impact factor: 2.980

Review 3.  Validated methods for assessment of subclinical atherosclerosis in rheumatology.

Authors:  György Kerekes; Pál Soltész; Michael T Nurmohamed; Miguel A Gonzalez-Gay; Maurizio Turiel; Edit Végh; Yehuda Shoenfeld; Iain McInnes; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2012-02-21       Impact factor: 20.543

4.  Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients.

Authors:  Fernanda Genre; Raquel López-Mejías; José A Miranda-Filloy; Begoña Ubilla; Verónica Mijares; Beatriz Carnero-López; Inés Gómez-Acebo; Trinidad Dierssen-Sotos; Sara Remuzgo-Martínez; Ricardo Blanco; Trinitario Pina; Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay
Journal:  Rheumatol Int       Date:  2015-07-05       Impact factor: 2.631

Review 5.  Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapies.

Authors:  Eric Toussirot
Journal:  Drugs Aging       Date:  2010-07-01       Impact factor: 3.923

6.  Evaluation of various endothelial biomarkers in ankylosing spondylitis.

Authors:  Ali Taylan; Ismail Sari; Didem L Kozaci; Yasar Yildiz; Safak Bilge; Isil Coker; Sergir Maltas; Necati Gunay; Nurullah Akkoc
Journal:  Clin Rheumatol       Date:  2011-05-10       Impact factor: 2.980

Review 7.  Metabolic syndrome and chronic arthritis: effects of anti-TNF-α therapy.

Authors:  Nicola Maruotti; Francesca d'Onofrio; Francesco Paolo Cantatore
Journal:  Clin Exp Med       Date:  2014-11-27       Impact factor: 3.984

Review 8.  Sex and Cardiovascular Involvement in Inflammatory Joint Diseases.

Authors:  Santos Castañeda; Carlos González-Juanatey; Miguel A González-Gay
Journal:  Clin Rev Allergy Immunol       Date:  2019-06       Impact factor: 8.667

9.  [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Authors:  U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

10.  Factors associated with accelerated subclinical atherosclerosis in patients with spondyloarthritis without overt cardiovascular disease.

Authors:  Alessandro Giollo; Andrea Dalbeni; Giovanni Cioffi; Federica Ognibeni; Davide Gatti; Luca Idolazzi; Giovanni Orsolini; Pietro Minuz; Maurizio Rossini; Cristiano Fava; Ombretta Viapiana
Journal:  Clin Rheumatol       Date:  2017-09-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.